Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | FCR or FR – which regimen is better for treating CLL?

Susan O’Brien • 1 Jun 2017
ASCO 2017
Chronic Lymphocytic Leukemia Cyclophosphamide Fludarabine Rituximab

Susan O’Brien, MD from the University of California, Irvine, CA provides us an overview of the current treatment of chronic lymphocytic leukemia (CLL) at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL. The results from the CLL8 trial, in which the efficacies of FCR and FR in treating CLL patients were compared, are also mentioned here (NCT00281918). She also explains the need for validating the superiority of FCR over FR in treating CLL patients who are candidates for chemoimmunotherapy, which was evaluated in this trial.

More from Susan O’Brien

2:03
Venetoclax and obinutuzumab combination therapy for CLL
Susan O’Brien • 14 Jun 2019
2:19
CAR T-cell therapy updates in CLL
Susan O’Brien • 14 Jun 2019
2:00
CLL RESONATE-2: Five-year follow-up
Susan O’Brien • 13 Jun 2019
3:19
Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib?
Susan O’Brien • 15 Jun 2019

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals